Institute for Biomedicine - News & Events - Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?
Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?
We discuss these issues on October 5th 2021 from 2.00pm on, during the Virtual Symposium organized by the Interreg European project "Epigenetics of Immunity in Cancer".
- Deutsch
- English
- Italiano
- Date: 05.10.2021, From 2:00 pm
- Place: Zoom
- Typology: Virtual Symposium
October 5th 2021 - from 2.00 pm - Virtual Symposium - "Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?"
The Epigenetics of Immunity in Cancer (EPIC) project, funded by ERDF / Interreg V-A Italy-Austria 2014-2020 (ITAT1054), aims to improve the effectiveness of existing cancer therapies by utilizing specific compounds that elicit an immune response against tumors. Cancer cells undergo epigenetic changes that allow them to pass undetected by the immune system and keep proliferating. With the use of histone deacetylase inhibitors, we focus on reverting those epigenetic changes, restoring the expression of genes that allow cancer cells to be once again sensible to therapy and be recognized by the immune response.
This EPIC symposium features dedicated information on several aspects of the interaction between histone deacetylases, their inhibitors and the immune system. Five international scientists will present ongoing research and share insights on cancer epigenetics - specific attention will be given to MEF2, a class of transcription factors strictly connected to histone deacetylase activity in driving the epigenetic changes in cancer cells.
The symposium is free of charge and will be held via Zoom. In order to attend it, please register by sending an email to ricerca.dame@uniud.it indicating: I would like to attend to the Fall EPIC symposium entitled "Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?"
